Arbutus Biopharma Corpora... (ABUS)
NASDAQ: ABUS
· Real-Time Price · USD
3.40
0.02 (0.59%)
At close: Aug 19, 2025, 11:44 AM
0.59% (1D)
| Bid | 3.4 |
| Market Cap | 652.74M |
| Revenue (ttm) | 15.42M |
| Net Income (ttm) | -54.25M |
| EPS (ttm) | -0.29 |
| PE Ratio (ttm) | -11.74 |
| Forward PE | -17.87 |
| Analyst | Buy |
| Ask | 3.41 |
| Volume | 283,703 |
| Avg. Volume (20D) | 747,935 |
| Open | 3.38 |
| Previous Close | 3.38 |
| Day's Range | 3.35 - 3.41 |
| 52-Week Range | 2.71 - 4.72 |
| Beta | 0.86 |
About ABUS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ABUS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ABUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Arbutus Biopharma Corporation is scheduled to release its earnings on
Nov 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-0.9%
ABUS stock has given up its prior gain. Arbutus Bi...
Unlock content with
Pro Subscription
3 months ago
-0.9%
Arbutus Biopharma shares are trading higher after the company presented clinical trial data from its two HBV assets.
